• Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the british society of gene and cell therapy annual meeting 2015.

      Gilham, David E; Anderson, J; Bridgeman, J; Hawkins, Robert E; Exley, M; Stauss, H; Maher, J; Pule, M; Sewell, A; Bendle, G; et al. (2015-05)
      Adoptive T-cell therapy is delivering objective clinical responses across a number of cancer indications in the early phase clinical setting. Much of this clinical activity is taking place at major clinical academic centers across the United States. This review focuses upon cancer-focused cell therapy activity within the United Kingdom as a contribution to the 2015 British Society of Gene and Cell Therapy annual general meeting. This overview reflects the diversity and expansion of clinical and preclinical studies within the United Kingdom while considering the background context of this work against new infrastructural developments and the requirements of nationalized healthcare delivery within the UK National Health Service.
    • CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.

      Gilham, David E; Debets, R; Pule, M; Hawkins, Robert E; Abken, Hinrich; Clinical and Experimental Immunotherapy Group, School of Cancer and Enabling Sciences, The University of Manchester, Withington, Manchester M20 4BX, UK. dgilham@picr.man.ac.uk (2012-07)
      Recent reports on the impressive efficacy of adoptively transferred T cells to challenge cancer in early phase clinical trials have significantly raised the profile of T cell therapy. Concomitantly, general expectations are also raised by these reports, with the natural aspiration to deliver this therapy over a wide range of tumor indications. Chimeric antigen receptors (CARs) endow T cell populations with defined antigen specificities that function independently of the natural T cell receptor and permit targeting of T cells towards virtually any tumor. Here, we review the current clinical application of CAR-T cells and relate clinical efficacy and safety of CAR-T cell trials to parameters considered critical for CAR engineering, classified as the three T's of CAR-T cell manipulation.